Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 241-924-6 | CAS number: 18016-43-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP Guideline Study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442B (Skin Sensitization: Local Lymph Node Assay: BrdU-ELISA)
- GLP compliance:
- yes
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- Oleic acid, compound with N-(2-aminoethyl)ethane-1,2-diamine
- EC Number:
- 241-924-6
- EC Name:
- Oleic acid, compound with N-(2-aminoethyl)ethane-1,2-diamine
- Cas Number:
- 18016-43-8
- Molecular formula:
- C38H69N3O – C58H111N3O3
- IUPAC Name:
- (9Z)-octadec-9-enoic acid; bis(2-aminoethyl)amine
- Details on test material:
- - Name of test material (as cited in study report): Oleic acid, compound with N-(2-aminoethyl)ethane-1,2-diamine
- Physical state: liquid
- Analytical purity: Reaction product of Oleic acid and N-(2-aminoethyl)ethane-1,2- diamine: Elemental-analysis yielded 100.4 g/100g
"Triamide"-content : 5.2 g/100g determined by HPLC-analysis (for details see analytical report No. 11L00415)
- Lot/batch No.: 11000829U0
- Stability under test conditions: The stability of the test item under storage conditions over the test period will be guaranteed by the sponsor, and the sponsor holds this responsibility.
- Storage condition of test material: Ambient (RT)
Constituent 1
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan Winkelmann GmbH, Borchen, Germany
- Age at study initiation: 8-10 weeks (pretest), 10 weeks (main test)
- Weight at study initiation: 19.1-22.5 g (main test)
- Housing: Single housing in Makrolon cages, type II with bedding (H 15005-29; Ssniff. Spezialitäten GmbH (Experimental Animal Diets Inc., 59494 Soest, Germany))
- Diet: STANRAB (P) SQC; SDS Special Diets Services. 67122 Altrip, Germany ad libitum
- Water: Tap water ad libitum
- Acclimation period: at least 5 days prior to the start of dosing
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 30 - 70
- Air changes (per hr): approx. 10
- Photoperiod (hrs dark / hrs light): 12 / 12
Study design: in vivo (LLNA)
- Vehicle:
- acetone/olive oil (4:1 v/v)
- Concentration:
- 0.1, 0.25 and 0.5 %
- No. of animals per dose:
- 5
- Details on study design:
- RANGE FINDING TESTS:
- Compound solubility: The highest test item concentration, which could be technically used, was 100% (w/w). In lower concentrations AOO was used as vehicle.
- Irritation: At the tested concentrations of 1, 2.5, 5, 10, 25, 50 and 100% the animals showed signs of local irritation as confirmed by the ear weight measurements. All animals in these dose groups showed exceeded thresholds with increased ear weights > 25%. Animals in these
dose groups also showed ear swellings > 25%. In addition erythema, swelling and hardening of the ears, incrustations, scaling and test item residues were observed in dose group 50 and 100%. In dose group 10 and 25% erythema, ear swelling and test item residues were noted. Erythema, ear swelling, scaling and incrustations were observed in dose group 2.5 and 5%. In dose group 1% erythema, scaling and incrustations were
noted, in dose group 0.5% scaling was observed. The vehicle animals were in a normal range concerning ear weight measurements and ear swelling. Animals in dose group 0.5% didn`t show increased ear weights > 25%. One animal in dose group 0.5% revealed ear swellings > 25%. Due to the fact that concurrent ear weight measurements were below the threshold and that the ear thickness value (27%) in one animal only marginally exceeded
the threshold of 25% (and in which error of measurement is possible to some extent), the following dose levels were selected for the main study: 0.5%, 0.25% and 0.1% (w/w) in acetone:olive oil (4:1,v/v).
- Lymph node proliferation response: Not determined.
MAIN STUDY
TREATMENT PREPARATION AND ADMINISTRATION:
Test Item Preparation
The test item preparations were produced individually on a weight per weight (w/w) basis shortly before application by stirring with a magnetic stirrer. The homogeneity of the test item preparation during application was ensured by stirring with a magnetic stirrer.
Topical Application
Each test group of mice was treated by topical (epidermal) application to the dorsal surface of each ear with test item concentrations of 0.1, 0.25 and 0.5 % (w/w) in AOO. The application volume 25 μL/ear/day was spread over the entire dorsal surface of each ear once daily for three consecutive days. The control test group of mice was treated with an equivalent volume of the relevant vehicle alone. The positive control test group of mice was treated with 25 % α-hexyl cinnamaldehyde dissolved in AOO.
Administration of BrdU
BrdU was purchased from Roche Diagnostics GmbH. For injection it was dissolved in DPBS (10 mg/mL) before administration and stored in a refrigerator until use. Four days after the first topical application (day 5) 0.5 mL of BrdU solution (5mg/per mouse/injection) were intraperitoneally injected.
Determination of Incorporated BrdU
Approximately 24 hours after treatment with BrdU the mice were sacrificed and the draining lymph nodes were rapidly excised and pooled for each animal (2 nodes per animal). Single cell suspensions of pooled lymph node cells were prepared by gentle mechanical disaggregation through a 70 μm nylon mesh. The lymph node cells were resuspended in 6 mL DPBS. After cell count with a cell counter (Casy Cell Counter. Innovatis), cell suspensions of 100 000 cells / mL were adjusted.
The incorporation of BrdU into lymph node cells was determined using a commercial cell proliferation assay kit (Roche Applied Science. Mannheim):
100 μL of the lymph node cell suspension (100 000 cells /mL) were added to the wells of a flat-bottom microplate in triplicate. After fixation and denaturation of the lymph node cells with FixDenat (included in Cell Proliferation Elisa Kit), anti BrdU antibody was added to each well and allowed to react. Subsequently the anti-BrdU antibody was removed by washing and the substrate solution TMB (included in Cell Proliferation Elisa Kit) was then added and allowed to produce chromogen. After stopping the substrate reaction the absorbance was measured at 450 nm with a reference wavelength of 690 nm.
Determination of Lymph Node Weight and Cell Count
After excision, the lymph nodes were pooled per animal and weighed immediately using an analytical balance.
Furthermore, the lymph node cell count was determined for each animal. For this, the volume of the cell suspensions mentioned in section 8.3.3 was adjusted to an equal final volume and vortexed. Subsequently, individual cell counts were determined using a cell counter (Casy Cell Counter, Innovatis). The values obtained were taken down manually.
Determination of Ear Weights
After the lymph nodes were excised, both ears of mice were punched at the apical area using a biopsy punch (Stiefel, Ø 8 mm corresponding to 0.5 cm2). For each animal both punches were immediately weighed (pooled per animal) using an analytical balance.
Interpretation of Raw Data
The proliferative response of the lymph node cells is expressed as the mean SI. The SI is derived by dividing the mean BrdU labeling index/mouse within each test substance group as well as for the positive control group by the mean BrdU labeling index for the vehicle group.
A test item is regarded as a sensitizer in the LLNA if the following criteria are fulfilled:
- First, that exposure to at least one concentration of the test item resulted in an incorporation of BrdU at least 1.6-fold or greater than that recorded in control mice, as indicated by the Stimulation Index.
- Second, that the data are compatible with a conventional dose response, although allowance must be made (especially at high topical concentrations) for either local toxicity or immunological suppression.
Furthermore, an index was calculated for the lymph node weight and -cell count as well as for the ear weight by dividing the mean values of the test item treated groups by the mean of the vehicle control group. For BALB/c mice, a cutoff-value for the lymph node cell count index of 1.55 was reported for a positive response.Furthermore, according to OECD guideline 442B, an increase in ear weight exceeding the threshold value of 25% was considered to be indicative for excessive local skin irritation.
Observations
In addition to the sensitizing reactions the following observations and data were recorded during the test and observation period:
- Mortality / Viability: At least once daily from experimental start to necropsy
- Body weights: Prior to the first application and prior to sacrifice (pretest and main experiment)
- Ear thickness: In the pre-test prior to the first application of the test item (day 0), on day 2 and before sacrifice (day 5) the ear thickness was determined using a micrometer (S0247 Kroeplin, 36381 Schlüchtern, Germany)
- Ear weights: In the pre-test and main experiment after sacrifice; biopsy punches were taken from each ear
- Lymph node weights: After excision, the lymph nodes were pooled per animal and weighed immediately using an analytical balance
- Lymph node cell count: The lymph node cell count was determined in aliquots taken from the prepared single cell suspensions of the lymph nodes using a cell counter
- Clinical signs (local / systemic): Clinical signs (local irritation at the application site or systemic toxicity) were recorded at least once daily. Especially the treatment sites were observed carefully. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- The mean values and standard deviations were calculated in the body weight tables, for the ear weights, the lymph node weights and lymph node cell count, and for the BrdU values. A statistical analysis was conducted on the BrdU values, the ear weights, the lymph node weights and the lymph node cell count to assess whether the difference was statistically significant between test item groups and negative control group. For all statistical calculations Statistica (Version 10) was used. A One-Way-Analysis-of-Variance was used as statistical method. In case of significant results of the One-Way-ANOVA, multiple comparisons were performed with the Dunnett test or the Student Newman Keuls test. Statistical significance was set at the five per cent level (p < 0.05). However, both biological and statistical significance were considered together.
Results and discussion
In vivo (LLNA)
Resultsopen allclose all
- Parameter:
- SI
- Remarks on result:
- other: see Remark
- Remarks:
- Concentration (% w/w) Stimulation index Result 0 1.0 - 0.1 1.2 negative 0.25 1.0 negative 0.5 1.4 negative
- Parameter:
- other: disintegrations per minute (DPM)
- Remarks on result:
- other: see Remark
- Remarks:
- Concentration (% w/v) Mean BrdU labeling Index 0 0.077 0.1 0.089 0.25 0.076 0.5 0.104
Any other information on results incl. tables
Viability / Mortality
No deaths occurred during the study period.
Clinical Signs
No symptoms of systemic toxicity were observed during the study period. In the high dose group (0.5%) scaling was observed at the last day of observation.
Body Weights
The body weight of the animals recorded prior to the first application and prior to sacrifice were within the range commonly recorded for animals of this strain and age.
Lymph Node Weights and Cell Counts
The measured lymph node weights and –cell counts of all animals treated were recorded after sacrifice. A statistically significant or biologically relevant increase in lymph node weights was not observed in any of the test item treated groups in comparison to the vehicle control group. In dose group 0.5% lymph node cell count reached statistically significance without reaching biological relevance. No biological relevance or statistical significance was observed in the other test groups in this regard.
Ear Weights
The measured ear weights of all animals treated were recorded after sacrifice. A statistically significant increase in ear weights was not observed in dose group 0.1 and 0.25%, but in 0.5% in comparison to the vehicle control group. According to OECD guideline 442B, an increase in ear weight exceeding the threshold value of 25% was considered to be indicative for excessive local skin irritation. This threshold was not exceeded in any test item treated group.
Applicant's summary and conclusion
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.